YONKERS, N.Y., July 8, 2009 (GLOBE NEWSWIRE) -- Aureon Laboratories, Inc., a specialized laboratory dedicated to advancing personalized cancer treatment through predictive pathology, today announced the peer-reviewed results from its prostate cancer study published in the July 2009 issue of the Journal of Urology. The study demonstrates that Aureon’s patented approach of integrating morphometry and biomarker data with clinical information improves accuracy for identifying which patients are most likely to develop disease progression post-surgery.
